Who
Gregory M. Weinhoff
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Centessa Pharmaceuticals; Principal Financial Officer, Axovant Sciences; Director, Amicus Therapeutics.
In numbers
- Trades disclosed
- 113
- Buys
- 1
- Sells
- 20
- Bought
- $200K
- Sold
- $9.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 5 Jun 2007
- Last trade
- 24 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 24 Jun 2026 | Centessa PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —65,925 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —584,321 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —230,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —584,321 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —230,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —31,002 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —125,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —123,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —319,660 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —31,002 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —123,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —319,660 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticals | SEC FORM 4 Code D | —65,925 | filing |
| 26 Mar 2026filed 26 Mar 2026 | Centessa PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $92K23,998 at $3.85 | filing |
| 26 Mar 2026filed 26 Mar 2026 | Centessa PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $720K23,998 at $30.00 | filing |
| 26 Mar 2026filed 26 Mar 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,998 at $0.00 | filing |
| 26 Mar 2026filed 26 Mar 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —23,998 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.